Merck: another step forward for cancer drug Keytruda
(CercleFinance.com) - Merck and Japan's Eisai said that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation for the combination of Keytruda and Lenvima for the treatment of metastatic endometrial carcinoma.
This is the second breakthrough therapy designation for the Keytruda/Lenvima combination following advanced and/or metastatic renal cell carcinoma in January 2018.
The combination therapy is being jointly developed by Eisai and Merck as part of a strategic collaboration that was announced in March 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
This is the second breakthrough therapy designation for the Keytruda/Lenvima combination following advanced and/or metastatic renal cell carcinoma in January 2018.
The combination therapy is being jointly developed by Eisai and Merck as part of a strategic collaboration that was announced in March 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.